News

The FDA approved adjuvant nivolumab for the treatment of patients with resected esophageal or gastroesophageal (GEJ) cancer who have previously had neoadjuvant chemoradiation treatment.

When clinicians had a standard tool to refer patients to palliative care, quality of care and patient referrals were both improved, according to a recent study.

Better prognostic understanding led to earlier use of palliative care and more DNRs in patients with late-stage cancer.

The United States Preventative Services Task Force now recommends colorectal cancer screening to start at 45 years old.

There is no fall risk assessment that is specific to oncology, but one could be helpful in preventing accidents.

The FDA has approved pegcetacoplan (Empaveli) for the treatment of adults with paroxysmal nocturnal hemoglobinuria who are treatment naïve and those who are switching from the C5 inhibitors eculizumab (Soliris) and ravulizumab (Ultomiris).

An intervention to decrease chemotherapy wait times led to better patient satisfaction and reduced anxiety.

The FDA has granted a breakthrough device designation to the Avenda Health Focal Therapy System, a male “lumpectomy” product under development to treat patients with prostate cancer in office while preserving quality of life.

When in-person classes on central venous catheter care were limited due to the COVID-19 pandemic, educational videos became even more important.

In honor of Nurses' Week, from May 6-12, we’re sharing what some patients, survivors, and caregivers had to say about how oncology nurses helped them along their cancer journey.

The FDA has granted a priority review to the supplemental new drug application for ivosidenib tablets as a treatment option for patients with previously treated, IDH1-mutant cholangiocarcinoma.

The FDA granted an accelerated approval to pembrolizumab plus trastuzumab, fluoropyrimidine- and platinum-containing chemotherapy for the frontline treatment of patients with locally advanced unresectable or metastatic HER2-positive gastric or gastroesophageal junction adenocarcinoma.

The rolling submission of a new drug application to the FDA for surufatinib for the treatment of patients with pancreatic and non-pancreatic neuroendocrine tumors has been completed.

The FDA has granted a priority review designation to a supplemental biologics license application for nivolumab for use as an adjuvant treatment in patients with surgically resected, high-risk, muscle-invasive urothelial carcinoma.

Each month, we take a look back at the most popular Oncology Nursing News® stories. Here are the top 5 stories from April 2021.

A recent study analyzed the benefits and work-related stressors of end-of-life care.

Breast cancer survivors may experience an increase in fear of recurrence after undergoing genomic testing that reveals risk.

The FDA has granted an accelerated approval to loncastuximab tesirine for the treatment of adult patients with relapsed/refractory large B-cell lymphoma following 2 or more lines of systemic therapy.

The current scale often used to measure nurse quality of life may be missing some key factors, according to recent research.

The use of a smartphone mobile app showed that patients with cancer had higher adherence to oral chemotherapy regimens, especially when it came to safely monitoring chemotherapy toxicity and symptoms in real time.

The FDA approved dostarlimab (Jemperli) for the treatment of patients with recurrent or advanced endometrial cancer that progressed on or after platinum-containing chemotherapy and whose cancer is DNA mismatch repair deficient (dMMR), as determined by an FDA-approved test.

More than one-third of adults report delaying or forgoing health care either because of fear of infection or their physicians offering limited services.

The FDA approved nivolumab (Opdivo) plus certain types of chemotherapy for the treatment of patients with advanced or metastatic gastric cancer, gastroesophageal junction (GEJ) cancer, and esophageal adenocarcinoma.

The FDA has granted a rare pediatric disease designation to the p-STAT3 inhibitor WP1066 for the treatment of patients with ependymoma, a rare type of tumor that can develop in the brain or the spinal cord.

The FDA granted an accelerated approval to sacituzumab govitecan (Trodelvy) for patients with locally advanced or metastatic urothelial cancer (mUC) who previously had a platinum-containing chemotherapy and a PD-1 or PD-L1 inhibitor.

An Arkansas law may lay the groundwork for unfair care in certain populations, but there are always nurses and other clinicians ready to advocate for all of their patients.

The FDA has authorized the marketing of the first device that utilizes artificial intelligence based on machine learning to help clinicians detect lesions like polyps or suspected tumors in the colon in real time during a colonoscopy.

Lifileucel produced durable responses in advanced melanoma that was previously treated an an immunotherapy agent.

Caregivers have their own set of issues and anxieties, but a telehealth support service may help.

The information provided by the assessment is essential as it contributes to shared decision making. The goal of shared decision-making is for patients and clinicians to partner together and make informed choices based on the patient’s needs, values and preferences.